References

Unresolved reference

2025 · External reference

Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research

10.1016/j.jtct.2023.03.007 · 2023 · External reference

National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

10.1200/jco.20.03502 · 2021 · External reference

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation

10.1200/jco-25-00856 · 2025 · External reference

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide

10.1182/bloodadvances.2020003005 · 2021 · External reference

Increased infections and delayed CD4(+) T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation

10.1016/j.jtct.2021.07.023 · 2021 · External reference

Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation

10.1016/j.jaccao.2021.02.011 · 2021 · External reference

Post-transplantation cyclophosphamide is associated with increased bacterial infections

10.1038/s41409-023-02131-z · 2024 · External reference

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

10.1182/blood.2020009362 · 2021 · External reference

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide

10.1016/j.jtct.2024.12.006 · 2025 · External reference

Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

10.1038/s41409-021-01328-4 · 2021 · External reference

Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching

10.1038/s41409-020-01092-x · 2021 · External reference

Unresolved reference

2017 · External reference

International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium

10.1016/j.bbmt.2015.09.001 · 2016 · External reference

Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype

10.1016/j.bbmt.2010.02.024 · 2010 · External reference

Semiparametric regression for the mean and rate functions of recurrent events

10.1111/1467-9868.00259 · 2000 · External reference

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: results from the NMDP sponsored ACCESS study

10.1182/blood-2025-936 · 2025 · External reference

Infectious risk after allogeneic hematopoietic cell transplantation complicated by acute graft-versus-host disease

10.1016/j.bbmt.2016.12.630 · 2017 · External reference

Incidence and outcomes of bacterial bloodstream infections during acute graft-versus-host disease involving the gastrointestinal tract after hematopoietic cell transplantation

10.1016/j.bbmt.2019.04.016 · 2019 · External reference

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic

10.1182/bloodadvances.2023009786 · 2023 · External reference

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

10.1182/bloodadvances.2022009231 · 2023 · External reference

Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR

10.1016/j.jtct.2025.05.014 · 2025 · External reference

Existence of HLA-mismatched unrelated donors closes the gap in donor availability regardless of recipient ancestry

10.1016/j.jtct.2023.08.014 · 2023 · External reference

Excellent 3-year survival in recipients of mismatched unrelated donor transplants using post-transplant cyclophosphamide: longer term outcomes of a National Marrow Donor Program-sponsored prospective clinical trial

10.1016/j.jtct.2022.12.017 · 2023 · External reference

Bacterial bloodstream infections in patients undergoing allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide

10.1016/j.jtct.2022.09.001 · External reference

Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation

10.1016/j.bbmt.2018.12.142 · 2019 · External reference

Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome

10.1016/j.jtct.2021.09.015 · 2022 · External reference

Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation

10.1111/bjh.17563 · 2021 · External reference

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant

10.1101/2025.02.25.25322901 · External reference

Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant

10.1001/jamanetworkopen.2019.18668 · 2020 · External reference

Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview

10.1038/sj.bmt.1702447 · 2000 · External reference

Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching

10.1016/j.bbmt.2020.01.013 · 2020 · External reference

Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis

10.1038/s41409-023-02010-7 · 2023 · External reference

Post-transplantation cyclophosphamide and tacrolimus for graft-versus-host disease prevention after allogeneic hematopoietic cell transplantation from HLA-matched donors has more advantages than limitations

10.1016/j.jtct.2023.11.020 · 2024 · External reference

Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin

10.1056/nejmoa2503189 · 2025 · External reference

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

10.1182/bloodadvances.2021005847 · 2022 · External reference

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

10.1056/nejmoa2215943 · 2023 · External reference

Sirolimus and cyclosporine with post-transplant cyclophosphamide or mycophenolate mofetil as graft-versus-host disease prophylaxis in unrelated donor hematopoietic cell transplantation

10.1200/jco-25-01238 · 2025 · External reference

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution

10.1182/bloodadvances.2021005139 · 2021 · External reference

Defining and grading infections in clinical trials involving hematopoietic cell transplantation: a report from the BMT CTN infectious disease technical committee

10.1016/j.jtct.2024.03.001 · 2024 · External reference